Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL
- PMID: 12740573
- DOI: 10.1038/nm876
Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL
Abstract
During the progression of atherosclerosis, autoantibodies are induced to epitopes of oxidized low-density lipoprotein (oxLDL) and active immunization of hypercholesterolemic mice with oxLDL ameliorates atherogenesis. We unexpectedly found that many autoantibodies to oxLDL derived from 'naive' atherosclerotic mice share complete genetic and structural identity with antibodies from the classic anti-phosphorylcholine B-cell clone, T15, which protect against common infectious pathogens, including pneumococci. To investigate whether in vivo exposure to pneumococci can affect atherogenesis, we immunized Ldlr(-/-) mice with Streptococcus pneumoniae. This induced high circulating levels of oxLDL-specific IgM and a persistent expansion of oxLDL-specific T15 IgM-secreting B cells primarily in the spleen, which were cross-reactive with pneumococcal determinants. Pneumococcal immunization decreased the extent of atherosclerosis, and plasma from these mice had an enhanced capacity to block the binding of oxLDL to macrophages. These studies show molecular mimicry between epitopes of oxLDL and S. pneumoniae and indicate that these immune responses can have beneficial effects.
Comment in
-
Autoimmunity: busting the atherosclerotic plaque.Nat Med. 2003 Jun;9(6):641-2. doi: 10.1038/nm0603-641. Nat Med. 2003. PMID: 12778153 No abstract available.
Similar articles
-
Humoral responses to oxidized low-density lipoprotein and related bacterial antigens after pneumococcal vaccine.Transl Res. 2007 Sep;150(3):172-9. doi: 10.1016/j.trsl.2007.04.001. Epub 2007 May 25. Transl Res. 2007. PMID: 17761370 Clinical Trial.
-
Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease.Minerva Cardioangiol. 2007 Dec;55(6):821-37. Minerva Cardioangiol. 2007. PMID: 18091649 Review.
-
Rethinking oxidized low-density lipoprotein, its role in atherogenesis and the immune responses associated with it.Arch Immunol Ther Exp (Warsz). 2004 Jul-Aug;52(4):225-39. Arch Immunol Ther Exp (Warsz). 2004. PMID: 15467487 Review.
-
Antibodies to oxidized LDL in atherosclerosis development--clinical and animal studies.Clin Chim Acta. 2004 Oct;348(1-2):1-8. doi: 10.1016/j.cccn.2004.05.021. Clin Chim Acta. 2004. PMID: 15369729 Review.
-
Phosphorylcholine-targeting immunization reduces atherosclerosis.J Am Coll Cardiol. 2007 Aug 7;50(6):540-6. doi: 10.1016/j.jacc.2006.11.054. Epub 2007 Jul 23. J Am Coll Cardiol. 2007. PMID: 17678738
Cited by
-
Immunity, atherosclerosis and cardiovascular disease.BMC Med. 2013 May 1;11:117. doi: 10.1186/1741-7015-11-117. BMC Med. 2013. PMID: 23635324 Free PMC article. Review.
-
Autoimmune diseases and atherosclerotic cardiovascular disease.Nat Rev Cardiol. 2024 Nov;21(11):780-807. doi: 10.1038/s41569-024-01045-7. Epub 2024 Jun 27. Nat Rev Cardiol. 2024. PMID: 38937626 Review.
-
Glycan Reactive Natural Antibodies and Viral Immunity.Viral Immunol. 2020 May;33(4):266-276. doi: 10.1089/vim.2019.0136. Epub 2019 Dec 17. Viral Immunol. 2020. PMID: 31851873 Free PMC article. Review.
-
Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans.J Clin Invest. 2009 May;119(5):1335-49. doi: 10.1172/JCI36800. Epub 2009 Apr 13. J Clin Invest. 2009. PMID: 19363291 Free PMC article.
-
Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids.Cardiovasc Res. 2019 Jan 1;115(1):179-189. doi: 10.1093/cvr/cvy136. Cardiovasc Res. 2019. PMID: 29850765 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases